As a member of the PARPs family sharing catalytic activity with PARP13 [14], previous investigations have demonstrated that PARP9 displays aberrant expression patterns in various tumors including breast, prostate, and cervical cancers; it is also associated with recurrent drug resistance within these malignancies [15–17]. This evidence concerns the gene PARP9 and cervical carcinoma.